BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34304673)

  • 21. Optimal timing to retrieve oocytes for fertility preservation in patients with acute myeloid leukemia: two cases of controlled ovarian stimulation using DuoStim with a literature review.
    Sekiguchi M; Ito A; Fukuda Y; Yoneyama M; Furui M; Nakaoka K; Umemura N; Hayashi Y; Tamaki Y; Katagiri Y; Nakata M
    Gynecol Endocrinol; 2023 Dec; 39(1):2217262. PubMed ID: 37271166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Specific protocols of controlled ovarian stimulation for oocyte cryopreservation in breast cancer patients.
    Cavagna F; Pontes A; Cavagna M; Dzik A; Donadio NF; Portela R; Nagai MT; Gebrim LH
    Curr Oncol; 2018 Dec; 25(6):e527-e532. PubMed ID: 30607119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual Triggering With Gonadotropin-Releasing Hormone Agonist and Standard Dose Human Chorionic Gonadotropin in Patients With a High Immature Oocyte Rate.
    Fabris AM; Cruz M; Legidos V; Iglesias C; Muñoz M; García-Velasco JA
    Reprod Sci; 2017 Aug; 24(8):1221-1225. PubMed ID: 28715965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fertility preservation: ovarian response to freeze oocytes is not affected by different malignant diseases-an analysis of 992 stimulations.
    von Wolff M; Bruckner T; Strowitzki T; Germeyer A
    J Assist Reprod Genet; 2018 Sep; 35(9):1713-1719. PubMed ID: 29869766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FERTILITY PRESERVATION IN YOUNG WOMEN WITH EARLY-STAGE BREAST CANCER.
    Vuković P; Kasum M; Raguž J; Lonjak N; Bilić Knežević S; Orešković I; Beketić Orešković L; Čehić E
    Acta Clin Croat; 2019 Mar; 58(1):147-156. PubMed ID: 31363337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different stimulation protocols for oocyte cryropreservation in oncological patients: a retrospective analysis of single university centre.
    Simi G; Obino ME; Casarosa E; Litta P; Artini PG; Cela V
    Gynecol Endocrinol; 2015; 31(12):966-70. PubMed ID: 26370262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
    Buendgen NK; Schultze-Mosgau A; Cordes T; Diedrich K; Griesinger G
    Arch Gynecol Obstet; 2013 Oct; 288(4):901-4. PubMed ID: 23545834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Random-start ovarian stimulation in patients with cancer.
    Cakmak H; Rosen MP
    Curr Opin Obstet Gynecol; 2015 Jun; 27(3):215-21. PubMed ID: 25919235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective assessment of follicular growth and the oocyte cohort after ovarian stimulation for fertility preservation in 90 cancer patients versus 180 matched controls.
    Decanter C; Robin G; Mailliez A; Sigala J; Morschhauser F; Ramdane N; Devos P; Dewailly D; Leroy-Martin B; Keller L
    Reprod Biomed Online; 2018 May; 36(5):543-551. PubMed ID: 29506861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.
    Haas J; Kedem A; Machtinger R; Dar S; Hourvitz A; Yerushalmi G; Orvieto R
    J Ovarian Res; 2014 Apr; 7():35. PubMed ID: 24694069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Random start controlled ovarian hyperstimulation for fertility preservation during incidental pregnancy: a case report of blastocyst vitrification from
    Şükür YE; Özkavukçu S; İlhan FC; Şimşir C; Sönmezer M
    Gynecol Endocrinol; 2019 Jul; 35(7):564-566. PubMed ID: 30798632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GnRH agonist and hCG (dual trigger) versus hCG trigger for follicular maturation: a systematic review and meta-analysis of randomized trials.
    Hu KL; Wang S; Ye X; Zhang D; Hunt S
    Reprod Biol Endocrinol; 2021 Jun; 19(1):78. PubMed ID: 34059045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
    Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
    Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study.
    European Recombinant LH Study Group
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2607-18. PubMed ID: 11397861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Priming Before In Vitro Maturation Cycles in Cancer Patients Undergoing Urgent Fertility Preservation: a Randomized Controlled Study.
    Sonigo C; Le Conte G; Boubaya M; Ohanyan H; Pressé M; El Hachem H; Cedrin-Durnerin I; Benoit A; Sifer C; Sermondade N; Grynberg M
    Reprod Sci; 2020 Dec; 27(12):2247-2256. PubMed ID: 32617881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ovarian stimulation is a safe and effective fertility preservation option in the adolescent and young adult population.
    Manuel SL; Moravek MB; Confino R; Smith KN; Lawson AK; Klock SC; Pavone ME
    J Assist Reprod Genet; 2020 Mar; 37(3):699-708. PubMed ID: 31828481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Random-start controlled ovarian stimulation for emergency fertility preservation in a patient with myelodysplastic syndrome: a case report.
    Cai H; Shen H
    Braz J Med Biol Res; 2016; 49(6):e5227. PubMed ID: 27191608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combining fertility preservation procedures to spread the eggs across different baskets: a feasibility study.
    Delattre S; Segers I; Van Moer E; Drakopoulos P; Mateizel I; Enghels L; Tournaye H; De Vos M
    Hum Reprod; 2020 Nov; 35(11):2524-2536. PubMed ID: 32951035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Which is the optimal timing for starting chemoprotection with gonadotropin-releasing hormone agonists after oocyte cryopreservation? Reflections on a critical case of ovarian hyperstimulation syndrome.
    Marin L; Vitagliano A; Capobianco G; Dessole F; Ambrosini G; Andrisani A
    J Gynecol Obstet Hum Reprod; 2021 Apr; 50(4):101815. PubMed ID: 32562778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Flexible ovarian stimulation in a poor responder: a case report and literature review.
    Xu B; Li Y
    Reprod Biomed Online; 2013 Apr; 26(4):378-83. PubMed ID: 23497915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.